'As we execute our strategy to build our consulting and services capabilities, this acquisition provides an excellent complement to our existing skills and practices portfolio,' said David M. Thomas, chairman and chief executive officer, IMS HEALTH. 'Cambridge Pharma expands our ability to support pharmaceutical decision making in a broader range of areas.'
IMS HEALTH currently offers consulting services that include portfolio assessment, specific product opportunity assessment, product market positioning, resource allocations for optimal product support, sales force effectiveness, and the management of information flow and delivery.
Cambridge Pharma Consultancy offers advisory services in practice areas that include business strategy, strategic market development, pricing and reimbursement and the strategic management of R&D.
'Joining the IMS HEALTH family will enable access to IMS HEALTH's industry-leading global pharmaceutical databases that track markets in more than 100 countries,' said Dr. Lindsey Matheson, chairman, Cambridge Pharma Consultancy. 'The combination of our two firms will create a powerful resource with global reach and unmatched skills and expertise to help our bio-pharmaceutical company clients achieve continued success.'
Founded in 1989 by Matheson and Dr. Joseph Zammit-Lucia, two physicians with experience in the pharmaceutical industry, Cambridge Pharma will operate as a division within IMS HEALTH's Global Consulting group, reporting to Murray Aitken, senior vice president, Global Consulting & Services, IMS HEALTH.
All articles 2006-22 written and edited by Mel Crowther and/or Nick Thomas unless otherwise stated.